SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Suzuki M, Tetsuka T, Yoshida S, Watanabe N, Kobayashi M, Matsui M, et al. The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF-α- or IL-1β-stimulated rheumatoid synovial fibroblast. FEBS Lett 2000; 465: 237.
  • 2
    Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397440.
  • 3
    Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85: 30710.
  • 4
    Durie FH, Fava RA, Noelle R. Short analytical review: collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 1994; 73: 118.
  • 5
    Sasai M, Saeki Y, Ohshima S, Nishioka K, Mima T, Tanaka T, et al. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6–deficient mice. Arthritis Rheum 1999; 42: 163543.
  • 6
    Goldring SR, Gravallese EM. Pathogenesis of bone lesions in rheumatoid arthritis. Curr Rheumatol Rep 2000; 4: 22631.
  • 7
    Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 18: 3049.
  • 8
    Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 2002; 30: 3406.
  • 9
    Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995; 38: 15160.
  • 10
    Feldmann M, Elliot MJ, Woody JN, Maini RN. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997; 64: 283350.
  • 11
    Breedveld FC. Future trends in the treatment of rheumatoid arthritis: cytokine targets. Rheumatology 1998; 38 Suppl 2: 113.
  • 12
    Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; 2: 2447.
  • 13
    Wooley PH, Duthcer J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993; 151: 66027.
  • 14
    Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleishmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 1417.
  • 15
    Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 47886.
  • 16
    Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999; 57: 94566.
  • 17
    Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 123844.
  • 18
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 155263.
  • 19
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 20
    Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000; 27: 84150.
  • 21
    Antoni C, Kalden JR. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (Infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 1999; 17 Suppl 18: S737.
  • 22
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 110510.
  • 23
    Arend WP. Interleukin-1 receptor antagonist: discovery, structure and properties. Prog Growth Factor Res 1990; 2: 193205.
  • 24
    Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43: 264859.
  • 25
    Gabay C, Marinova-Mutafchieva L, Williams RO, Gigley JP, Butler DM, Feldmann M, et al. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. Arthritis Rheum 2001; 44: 45162.
  • 26
    Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four–week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 61424.
  • 27
    Bemelmans MHA, Gouma DJ, Buurman WA. Influence of nephrectomy on TNF receptor clearance in murine model. J Immunol 1993; 150: 200717.
  • 28
    Lipsky PE, Kavanaugh A. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies. Rheumatology 1999; 38 Suppl 2: 414.
  • 29
    Kalden JR. How do the biologics fit into the current DMARD armamentarium? J Rheumatol 2001; 28 Suppl 62: 2735.
  • 30
    Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara M. Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol 1996; 314: 13742.
  • 31
    Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara M. FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock. Eur J Pharmacol 1997; 327: 16975.
  • 32
    Takahashi S, Keto Y, Fujita T, Uchiyama T, Yamamoto A. FR167653, a p38 mitogen-activated protein kinase inhibitor, prevents Helicobacter pylori-induced gastritis in Mongolian gerbils. J Pharmacol Exp Ther 2001; 296: 4856.
  • 33
    Kawashima Y, Takeyoshi I, Otani Y, Koibuchi Y, Yoshinari D, Koyama T, et al. FR167653 attenuates ischemia and reperfusion injury of the rat lung with suppressing p38 mitogen-activated protein kinase. J Heart Lung Transplant 2001; 20: 56874.
  • 34
    Yoshinari D, Takeyoshi I, Koibuchi Y, Matsumoto K, Kawashima Y, Koyama T, et al. Effects of a dual inhibitor of tumor necrosis factor-α and interleukin-1 on lipopolysaccharide-induced lung injury in rats: involvement of the p38 mitogen-activated protein kinase pathway. Crit Care Med 2001; 29: 62834.
  • 35
    Miyazawa K, Mori A, Miyata H, Akahane M, Ajisawa Y, Okudaira H. Regulation of interleukin-1-β-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase. J Biol Chem 1998; 273: 248328.
  • 36
    Van den Berg WB, Joosten LA, Helsen MM, van de Loo FA. Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin Exp Immunol 1994; 95: 23743.
  • 37
    Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB. Anticytokine treatment of established type II collagen–induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti–IL-1α/β, and IL-1Ra. Arthritis Rheum 1996; 39: 797809.
  • 38
    Mussener A, Litton MJ, Lindroos E, Klareskog L. Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997; 107: 48593.
  • 39
    Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin Exp Immunol 1997; 107: 50712.
  • 40
    Trentham D, Townes A, Kang A. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977; 146: 85768.
  • 41
    Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42: 253242.
  • 42
    Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Britti D, De Maio M, et al. Absence of endogenous interleukin-10 enhances the evolution of murine type-II collagen-induced arthritis. Eur Cytokine Netw 2001; 12: 56880.
  • 43
    Shiozawa S, Shimizu K, Tanaka K, Hino K. Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J Clin Invest 1997; 99: 12106.
  • 44
    Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. J Bone Miner Res 2000; 15: 147788.
  • 45
    Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, et al. Disease-modifying activity of SB242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000; 43: 17583.
  • 46
    Shinozaki T, Takagishi K, Tsutsumi S, Yanagawa T, Takeuchi K, Watanabe H, et al. Effect of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats. Mod Rheumatol 2001; 11: 3003.
  • 47
    Aiba M, Takeyoshi I, Sunose Y, Iwazaki S, Tsutsumi H, Ohwada S, et al. FR167653 ameliorates pulmonary damage in ischemia-reperfusion injury in a canine lung transplantation model. J Heart Lung Transplant 2000; 19: 87986.
  • 48
    Kobayashi N, Kataoka T, Ono A, Tsukimi Y, Okabe S. Role of p38 mitogen-activated protein kinase in the healing of gastric ulcers in rats. J Physiol Pharmacol 2001; 52: 195210.
  • 49
    Kitada H, Sugitani A, Yamamoto H, Otomo N, Okabe Y, Inoue S, et al. Attenuation of renal ischemia-reperfusion injury by FR167653 in dogs. Surgery 2002; 131: 65462.
  • 50
    Kong YM, Waldmann H, Cobbold S, Giraldo AA, Fuller BE, Simon LL. Pathogenic mechanisms in murine autoimmune thyroiditis: short- and long-term effects of in vivo depletion of CD4+ and CD8+ cells. Clin Exp Immunol 1989; 77: 42833.
  • 51
    Mozes E, Kohn LD, Hakim F, Singer DS. Resistance of MHC class I-deficient mice to experimental systemic lupus erythematosus. Science 1993; 261: 913.
  • 52
    Katz J, Benoist C, Mathis D. Major histocompatibility complex class I molecules are required for the development of insulitis in non-obese diabetic mice. Eur J Immunol 1993; 23: 335860.
  • 53
    Serreze DV, Leiter EH, Christianson GJ, Greiner D, Roopenian DC. Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes 1994; 43: 5059.
  • 54
    Wicker LS, Leiter EH, Todd JA, Renjilian RJ, Peterson E, Fischer PA, et al. Beta 2-microglobulin-deficient NOD mice do not develop insulitis or diabetes. Diabetes 1994; 43: 5004.
  • 55
    Zhang GX, Ma CG, Xiao BG, Bakhiet M, Link H, Olsson T. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats. Eur J Immunol 1995; 25: 11918.
  • 56
    Tada Y, Ho A, Koh D, Mak TW. Collagen-induced arthritis in CD4- or CD8-deficient mice: CD8+ T cells play a role in initiation and regulate recovery phase of collagen-induced arthritis. J Immunol 1996; 156: 45206.
  • 57
    Larsson P, Goldschmidt TJ, Klareskog L, Holmdahl R. Oestrogen-mediated suppression of collagen-induced arthritis in rats: studies on the role of the thymus and peripheral CD8+ T lymphocytes. Scand J Immunol 1989; 30: 7417.
  • 58
    Ehinger M, Vestberg M, Johnasson ACM, Johanesson M, Svensson A, Holmdahl R. Influence of CD4 or CD8 deficiency on collagen-induced arthritis. Immunology 2001; 103: 291300.
  • 59
    Moore KJ, Wada T, Barbee SD, Kelley VR. Gene transfer of RANTES elicits autoimmune renal injury in MRL-Faslpr mice. Kidney Int 1998; 53: 16318.
  • 60
    Wada T, Furuichi K, Segawa C, Shimizu M, Sakai N, Takeda S, et al. MIP-1α and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 1999; 56: 9951003.
  • 61
    Luster AD. Chemokine-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 43645.
  • 62
    Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem 2000; 275: 3115561.
  • 63
    Matsumoto M, Sudo T, Maruyama M, Osada H, Tsujimoto M. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor. FEBS Lett 2000; 486: 238.
  • 64
    Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, et al. A new anti-inflammatory compound, FR167653, ameliorates crescentic glomerulonephritis in Wistar-Kyoto rats. J Am Soc Nephrol 2000; 11: 153441.
  • 65
    Gardiner SM, Kemp PA, March JE, Bennett T. Influence of FR 167653, an inhibitor of TNF-alpha and IL-1, on the cardiovascular responses to chronic infusion of lipopolysaccharide in conscious rats. J Cardiovasc Pharmacol 1999; 34: 649.